Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1

Interventions

fludarabine phosphate 7Mycophenolic Acid 6Brentuximab Vedotin 6Whole-Body Irradiation 5Tacrolimus 5Rituximab 5Peripheral Blood Stem Cell Transplantation 5Cyclophosphamide 5Bortezomib 5Methotrexate 4Antilymphocyte Serum 4tanespimycin 3Radiotherapy 3Lenalidomide 3Filgrastim 3Etoposide 3Dasatinib 3Cyclosporine 3Cord Blood Stem Cell Transplantation 3merphos 2Vorinostat 2Vincristine 2Melphalan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Cyproheptadine 2Carboplatin 2Busulfan 2romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Large-Cell, Anaplastic × 7-hydroxystaurosporine × Clear all
NCT00082017 2017-05-15

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
20 enrolled 13 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡